Interim results from the first co-administration descriptive study of Sanofi’s Fluzone® High-Dose Quadrivalent vaccine with Moderna’s COVID-19 mRNA investigational booster dose show that the administration of the vaccines at the same visit had similar immunogenicity responses and a similar safety and tolerability profile compared to each vaccine administered individually.
Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations
October 11, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022